- Home
- NRXP vs MBOT Comparison
NRXP vs MBOT Comparison
Compare NRXP & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | MBOT |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | 29 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.2M | 114.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NRXP | MBOT |
|---|---|---|
| Price | $3.73 | $1.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $38.25 | $7.50 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,887.00 |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | $119.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.65 | $1.60 |
| 52 Week High | $5.06 | $4.62 |
Technical Indicators
Market Signals| Indicator | NRXP | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 48.47 | 42.92 |
| Support Level | $3.45 | $1.65 |
| Resistance Level | $3.84 | $2.21 |
| Average True Range (ATR) | 0.32 | 0.08 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 45.00 | 28.12 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About MBOT Microbot Medical Inc.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.